Citations

Mayo Clinic

Showing 10 of 108523 citations.

HepPar-1 and Arginase-1 Immunohistochemistry in Adenocarcinoma of the Small Intestine and Ampullary Region
Lagana, Stephen M. , Hsiao, Susan J. , Bao, Fei , Sepulveda, Antonia R. , Moreira, Roger K. , Lefkowitch, Jay H., Remotti, Helen , Lagana, Stephen

Archives of Pathology & Laboratory Medicine | June 2, 2015 | Volume: 139 | Issue: 6 | Pages: 791-795

10.5858/arpa.2013-0249-oa | PMID 26030248 Get It

Context HepPar-1 and Arginase-1 are urea cycle enzymes used to distinguish hepatocellular carcinoma from other carcinomas. HepPar-1, but not Arginase-1, is known to be immunoreactive with normal human small intestine. Objectives To better define and compare the immunohistochemical staining patterns of HepPar-1 and Arginase-1 in adenocarcinomas arising in the small intestine, including the ampullary region. Design Staining for HepPar-1 and Arginase-1 was performed on 20 nonampullary small intestinal adenocarcinomas and 32 adenocarcinomas from the ampullary region. Ampullary adenocarcinomas were divided into intestinal morphology (15), pancreatobiliary morphology (14), and unclassifiable (3). Nonneoplastic small intestinal mucosa and colorectal adenocarcinomas were used as control groups. Results HepPar-1 stained 12 of 20 nonampullary small intestinal adenocarcinomas, with a median of 63% of cells staining in positive cases. It also stained 11 of 15 ampullary carcinomas with intestinal morphology, with a median of 75% of cells staining in positive cases. Two of 14 ampullary carcinomas with pancreatobiliary morphology were positive for HepPar-1. Arginase-1 showed positivity in 2 ampullary region carcinomas and diffuse positivity in 1 duodenal adenocarcinoma. Two of 22 colorectal carcinomas stained for HepPar-1 with none positive for Arginase-1. Conclusions HepPar-1, but not Arginase-1, usually shows positivity in small intestinal adenocarcinomas and ampullary adenocarcinomas with intestinal morphology, but only rarely shows positivity in ampullary adenocarcinomas with pancreatobiliary morphology. HepPar-1 positivity in metastatic adenocarcinoma with intestinal morphology is suggestive of an upper gastrointestinal primary site.
Is Bronchiolitis Obliterans after Hematopoietic Stem Cell Transplantation Reversible?
Peters, Steve G.

American Journal of Respiratory and Critical Care Medicine | June 2, 2015 | Volume: 191 | Issue: 11 | Pages: 1214-1216

10.1164/rccm.201504-0720ed | PMID 26029830 Get It

Pseudomyxoma Pleuri. A Rare Manifestation of an Uncommon Disease
Gutiérrez, María del Valle Somiedo, Lee, Christine U. , Johnson, Geoffrey B. , Maldonado, Fabien , Johnson, Geoffrey B. , Villasboas, José C. , Shen, Robert K. , Johnson, Geoffrey B , Johnson, Geoffrey B

American Journal of Respiratory and Critical Care Medicine | June 2, 2015 | Volume: 191 | Issue: 11 | Pages: 1334-1335

10.1164/rccm.201412-2246im | PMID 26029839 Get It

Recent advances in 3D time-resolved contrast-enhanced MR angiography
Riederer, Stephen J. , Haider, Clifton R. , Borisch, Eric A. , Weavers, Paul T., Young, Phillip M.

Journal of Magnetic Resonance Imaging | June 2, 2015 | Volume: 42 | Issue: 1 | Pages: 3-22

10.1002/jmri.24880 | PMID 26032598 Get It

Anterior Closing Wedge Tibial Osteotomy for Failed Anterior Cruciate Ligament Reconstruction
Walker, Justin A. , Hartigan, David E. , Stuart, Michael J. , Krych, Aaron J.

Journal of Knee Surgery Reports | June 2, 2015 | Volume: 1 | Issue: 01 | Pages: 051-056

10.1055/s-0035-1551548 Get It

Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications
O’Carroll, Cumara B. , Aguilar, Maria I.

The Neurohospitalist | June 1, 2015 | Volume: 5 | Issue: 3 | Pages: 133-141

10.1177/1941874415587680 | PMID 26288671 Get It

Intravenous recombinant tissue plasminogen activator was first approved for the treatment of acute ischemic stroke in the United States in 1996. Thrombolytic therapy has been proven to be effective in acute ischemic stroke treatment and shown to improve long-term functional outcomes. Its use is associated with an increased risk of symptomatic intracerebral hemorrhage as well as orolingual angioedema. Our goal is to outline the management strategies for these postthrombolysis complications.
Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification
Escalante, Patricio , Peikert, Tobias, Keulen, Virginia P. Van , Erskine, Courtney L. , Bornhorst, Cathy L., Andrist, Boleyn R., McCoy, Kevin , Pease, Larry R. , Abraham, Roshini S. , Knutson, Keith L. , Kita, Hirohito , Schrum, Adam G. , Knutson, Keith L. , Limper, Andrew H. , Kita, H , Schrum, Adam G

American Journal of Respiratory and Critical Care Medicine | June 1, 2015 | Volume: 192 | Issue: 5 | Pages: 605-617

10.1164/rccm.201412-2141oc | PMID 26030344 Get It

Abstract Rationale Most immunocompetent patients diagnosed with latent tuberculosis infection (LTBI) will not progress to tuberculosis (TB) reactivation. However, current diagnostic tools cannot reliably distinguish nonprogressing from progressing patients a priori, and thus LTBI therapy must be prescribed with suboptimal patient specificity. We hypothesized that LTBI diagnostics could be improved by generating immunomarker profiles capable of categorizing distinct patient subsets by a combinatorial immunoassay approach. Objectives A combinatorial immunoassay analysis was applied to identify potential immunomarker combinations that distinguish among unexposed subjects, untreated patients with LTBI, and treated patients with LTBI and to differentiate risk of reactivation. Methods IFN-γ release assay (IGRA) was combined with a flow cytometric assay that detects induction of CD25+CD134+ coexpression on TB antigen–stimulated T cells from peripheral blood. The combinatorial immunoassay analysis was based on receiver operating characteristic curves, technical cut-offs, 95% bivariate normal density ellipse prediction, and statistical analysis. Risk of reactivation was estimated with a prediction formula. Measurements and Main Results Sixty-five out of 150 subjects were included. The combinatorial immunoassay approach identified at least four different T-cell subsets. The representation of these immune phenotypes was more heterogeneous in untreated patients with LTBI than in treated patients with LTBI or unexposed groups. Patients with IGRA(+) CD4+CD25+CD134+ T-cell phenotypes had the highest estimated reactivation risk (4.11 ± 2.11%). Conclusions These findings suggest that immune phenotypes defined by combinatorial assays may potentially have a role in identifying those at risk of developing TB; this potential role is supported by risk of reactivation modeling. Prospective studies will be needed to test this novel approach.
Anterior nuclear deep brain stimulation guided by concordant hippocampal recording
Klassen, Bryan T. , Lee, Kendall H. , Shin, Cheolsu, Zhao, Cong Zhi, Goerss, Steven J., Kall, Bruce A., Stead, Matt, Gompel, Jamie J. Van , Worrell, Gregory A. , Brown, Desmond , Goerss, S

Neurosurgical Focus | June 1, 2015 | Volume: 38 | Issue: 6 | Pages: E9

10.3171/2015.3.focus1541 | PMID 26030709 Get It

OBJECT Anterior nuclear (AN) stimulation has been reported to reduce the frequency of seizures, in some cases dramatically; however, it has not been approved by the US Food and Drug Administration. The anterior nucleus is difficult to target because of its sequestered location, partially surrounded by the ventricle. It has traditionally been targeted by using transventricular or lateral transcortical routes. Here, the authors report a novel approach to targeting the anterior nucleus and neurophysiologically confirming effective stimulation of the target, namely evoked potentials in the hippocampus. METHODS Bilateral AN 3389 electrodes were placed in a novel trajectory followed by bilateral hippocampal 3391 electrodes from a posterior trajectory. Each patient was implanted bilaterally with a Medtronic Activa PC+S device under an investigational device exemption approval. Placement was confirmed with CT. AN stimulation-induced hippocampal evoked potentials were measured to functionally confirm placement in the anterior nucleus. RESULTS Two patients had implantations by way of a novel AN trajectory with concomitant hippocampal electrodes. There were no lead misplacements. Postoperative stimulation of the anterior nucleus with a PC+S device elicited evoked potentials in the hippocampus. Thus far, both patients have reported a > 50% improvement in seizure frequency. CONCLUSIONS Placing AN electrodes posteriorly may provide a safer trajectory than that used for traditionally placed AN electrodes. In addition, with a novel battery that is capable of electroencephalographic recording, evoked potentials can be used to functionally assess the Papez circuit. This treatment paradigm may offer increased AN stimulation efficacy for medically intractable epilepsy by assessing functional placement more effectively and thus far has proven safe.
Optimum methodology for estimating baseline serum creatinine for the acute kidney injury classification
Cheungpasitporn, Wisit , Kittanamongkolchai, Wonngarm , Srivali, Narat , Ungprasert, Patompong , Thongprayoon, Charat , Kashani, Kianoush , Cheungpasitporn, Wisit , Srivali, Narat

Nephrology | June 1, 2015 | Volume: 20 | Issue: 12 | Pages: 881-886

10.1111/nep.12525 | PMID 26032233 Get It

AbstractAimThis study aimed to investigate how varied methods of determining baseline serum creatinine (SCr) would affect acute kidney injury (AKI) diagnosis and prediction of 60 day mortality in critically ill patients following an episode of AKI.MethodsThis is a single‐centre retrospective study conducted at a tertiary referral hospital. All adult intensive care unit (ICU) patients between January and December 2011, who had at least one SCr values measured between 7 days and 180 days before hospital admission and during ICU stay, were analyzed. The baseline SCr was calculated using either the most recent (SCrmost recent) or the minimum (SCrmin) value of SCr measurement over the specified assessment period before hospital admission. AKI was defined based on KDIGO SCr definition. The primary outcome was 60 day mortality after ICU admission.ResultsA total of 4020 patients were included in the analysis. AKI was detected in 1204 (30.0%) using the SCrmin and 945 (23.5%) using the SCrmost recent (P < 0.001). Compared with patients without AKI regardless of baseline SCr methodology, the 60 day mortality risk of patients who developed AKI using the SCrmin and SCrmost recent was significantly increased (odds ratio (OR) = 3.74; 95% confidence interval (CI) 2.98–4.70). Similarly, the risk of 60 day mortality in patients who met AKI criteria using the SCrmin but not the SCrmost recent was significant higher than in patients without AKI (OR = 2.04; 95% CI 1.36–3.00).ConclusionUsing the minimum value of preadmission SCr as a baseline kidney function not only can detect more AKI cases, but also provides the better predictive ability for 60 day mortality.
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7‐year PRECiSE 3 study
Sandborn, William J. , Melmed, Gil , Loftus, Edward V. , Cho, J.‐H. , Abraham, Bincy , Lichtenstein, Gary R. , Lee, S. D., Randall, Charles , Regueiro, Miguel, Spearman, Marshall, Kosutic, Gordana, Pierre‐Louis, Bosny, Coarse, Jason, McGovern, Dermot , Choi, J. M., Gutiérrez, Ana , Schwartz, David A. , Siegel, Corey A , Schreiber, Stefan , Loftus, Edward V , Melmed, Gil Y

Alimentary Pharmacology & Therapeutics | June 1, 2015 | Volume: 42 | Issue: 3 | Pages: 330-342

10.1111/apt.13251 | PMID 26031921 Get It

SUMMARYBackgroundClinical factors were previously identified as predictors of short‐term treatment efficacy in Crohn's disease (CD). The PRECiSE 3 (P3) 7‐year trial provides an opportunity to study predictors of short‐ and long‐term clinical remission among CD patients treated with certolizumab pegol (CZP).AimTo identify factors that influence long‐term remission of CD with CZP treatment.MethodsPatients who had completed placebo‐controlled studies (PRECiSE 1/PRECiSE 2, P1/P2) enrolled in P3 and received open‐label CZP 400 mg every 4 weeks up to 7 years. Baseline predictors included, but were not limited to, smoking status, disease duration, prior inflammatory bowel disease (IBD) surgery, Harvey–Bradshaw Index (HBI), albumin, haematocrit and CZP exposure; association with time to initial remission (HBI ≤4) was tested for patients who received CZP in P1/P2; time to loss of remission/frequency of maintenance of remission was also tested. Univariate analyses and multivariate Cox or logistic regression models were used.ResultsPredictors for initial remission (N = 377) included age, haematocrit, prior IBD surgery and entry HBI (P < 0.05 for all). Predictors for loss of remission (N = 437) included HBI, serum albumin concentration, haematocrit, smoking status and exposure. Predictors of maintenance of remission (N = 437) included haematocrit, IBD surgery, HBI, disease duration, serum albumin concentration and exposure. Significant predictors were confirmed with stepwise multivariate regression models.ConclusionsThese analyses identified several influential parameters for short‐and long‐term remission of Crohn's disease with certolizumab pegol treatment. The data yield valuable hypotheses regarding factors that influence certolizumab pegol treatment. More investigation is needed.(ClinicalTrials.gov identifier NCT00552058).